FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder... -- WAYNE, N.J., March 11 /PRNewswire/ --
Links shared publicly online about this topic.
- 1,322total visits
FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder... -- WAYNE, N.J., March 11 /PRNewswire/ --
FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis.
View full resource at prnewswire.com
Tags: Cystic Fibrosis, Drug, Healthcare, FDA, Antibiotic, Cipro, Bayer
Most Recently Shared on March 11, 2010 at 6:23 pm By:
Bayer gets orphan drug status for Cipro inhaler in PhII trials for cystic fibrosis: http://bit.ly/aBj0HQ
Advertisement
